





Date Written: December 2019

Review due: December 2021

## **Switching between Oral Anticoagulants**

From	То	How to Switch?
DOAC	DOAC	<ul> <li>Initiate when next dose is due except where higher plasma concentrations expected (e.g. renal impairment).</li> </ul>
Apixaban		<ul> <li>Start VKA and continue Apixaban for at least 2 days. After 2 days of coadministration an INR should be obtained before the next scheduled dose of Apixaban.</li> <li>Coadministration should be continued until the INR is ≥2.0.</li> </ul>
Rivaroxaban	Vitamin K Antagonist (VKA)	<ul> <li>Rivaroxaban = Start VKA and continue Rivaroxaban until the INR is ≥2.0. While patients are on both Rivaroxaban and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Rivaroxaban.</li> </ul>
Dabigatran		<ul> <li>VKA should be started according to renal function. If:</li> <li>○ CrCL ≥ 50 mL/min, VKA should be started 3 days before discontinuing Dabigatran</li> <li>○ CrCL ≥ 30 - &lt;50 mL/min, VKA should be started 2 days before discontinuing Dabigatran</li> </ul>
Edoxaban	-	Edoxaban = See SPC <u>via this link.</u>
Vitamin K Antagonist (VKA)	Apixaban	Stop VKA and commence Apixaban once INR is <2.0.
	Rivaroxaban	<ul> <li>Rivaroxaban = Stop VKA and commence Rivaroxaban once:</li> <li>○ INR is ≤3.0 if for prevention of stroke and systemic embolism.</li> <li>○ INR is ≤2.5 if for DVT, PE and prevention of recurrence.</li> </ul>
	Dabigatran	Stop VKA and commence Dabigtran once INR is <2.0.
	Edoxaban	Stop VKA and start Edoxaban once INR is ≤2.5.